Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

Related Citations for PubMed (Select 15661210)

1.

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR.

Gynecol Oncol. 2005 Feb;96(2):287-95.

PMID:
15661210
2.

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.

Gynecol Oncol. 2004 Jul;94(1):67-73.

PMID:
15262121
3.

Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.

Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V.

Gynecol Oncol. 1998 Sep;70(3):398-403.

PMID:
9790794
4.

Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.

McAlpine JN, Eisenkop SM, Spirtos NM.

Gynecol Oncol. 2008 Sep;110(3):360-4. doi: 10.1016/j.ygyno.2008.05.019. Epub 2008 Jul 15.

PMID:
18632143
5.

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.

6.

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group.

Ann Oncol. 2002 Nov;13(11):1749-55.

7.
8.

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.

Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, Denoyelle C, Gauduchon P, Poulain L.

Mol Cancer Ther. 2009 Nov;8(11):3162-70. doi: 10.1158/1535-7163.MCT-09-0493. Epub 2009 Nov 3.

9.

Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.

Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 May;105(2):373-84. Epub 2007 Feb 5.

PMID:
17276501
10.

Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M.

Cancer Biol Ther. 2010 Dec 1;10(11):1137-46. doi: 10.4161/cbt.10.11.13443. Epub 2010 Dec 1.

11.

Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.

Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO).

Onkologie. 2004 Feb;27(1):58-64.

PMID:
15007250
12.

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2012 Apr;11(4):1026-35. doi: 10.1158/1535-7163.MCT-11-0693. Epub 2012 Feb 1.

13.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

14.

Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.

Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L.

Int J Cancer. 2010 Feb 15;126(4):885-95. doi: 10.1002/ijc.24787.

PMID:
19634140
15.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
16.

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.

Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 Apr;105(1):31-44. Epub 2007 Feb 1.

PMID:
17275076
17.

[Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].

Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.

Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8. Chinese.

PMID:
21092551
18.

Future directions in the chemotherapy of ovarian cancer.

Ozols RF.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-86-S15-90. Review.

PMID:
9346230
19.

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Létourneau IJ, Quinn MC, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM.

BMC Cancer. 2012 Aug 29;12:379. doi: 10.1186/1471-2407-12-379.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk